CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial
Titel:
CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial
Auteur:
Lancet, Jeffrey E Uy, Geoffrey L Newell, Laura F Lin, Tara L Ritchie, Ellen K Stuart, Robert K Strickland, Stephen A Hogge, Donna Solomon, Scott R Bixby, Dale L Kolitz, Jonathan E Schiller, Gary J Wieduwilt, Matthew J Ryan, Daniel H Faderl, Stefan Cortes, Jorge E